Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

House Oversight Committee Takes on Pharma Industry

The House Committee on Oversight and Reform launched an investigation into prescription drug pricing practices.

Read More »

Novartis, China’s Gan & Lee push into insulin amid diabetes epidemic

Swiss drugmaker Novartis aims to become a big player in supplying insulin to swelling numbers of diabetics, signing a deal with China’s Gan & Lee on versions of three blockbuster brands as the U.S. government is seeking to slash insulin costs.

Read More »

Why Type One Diabetes Patients Need Closed Loop Insulin Systems

For a while now there has been a heated debate surrounding hybrid and closed loop insulin systems.

Read More »

Cost keeps many diabetics from taking needed insulin

The cost of insulin prevents many people with diabetes from taking it as directed, a small survey suggests.

Read More »

Minnesota accuses insulin makers of deceptive drug pricing

Minnesota’s attorney general filed a lawsuit accusing Sanofi, Novo Nordisk and Eli Lilly of deceptively raising prices for insulin.

Read More »

Novo Nordisk Acquires Ziylo in Possible $800 Million-Plus Deal

Copenhagen, Denmark-based Novo Nordisk acquired Bristol, UK-based Ziylo in a deal that could exceed $800 million.

Read More »

Obesity, diabetes in pregnancy may raise kids’ risk of psychiatric disorders

Pregnant women who have both severe obesity and diabetes may be more likely to have children with autism, ADHD and other psychiatric disorders than mothers who do not have either condition during pregnancy, a new study suggests.

Read More »

Recent Study Suggests Diabetes Treatment May Have Potential in Parkinson’s Disease

Research published in the journal Nature by researchers at the National Health Research Institutes in Taiwan and the National Institute on Aging, National Institutes of Health in the U.S. suggest that a class of diabetes medications known as GLP-1 analogs may be effective treatments for Parkinson’s disease.

Read More »

FDA approves Toujeo Max SoloStar

The U.S. Food and Drug Administration approved Sanofi’s Toujeo (insulin glargine 300 Units/mL) Max SoloStar, the highest capacity long-acting insulin pen that will be available on the market.

Read More »

In diabetes war, Novo Nordisk aims to break mold with new pill

After nearly a century building a company worth $125 billion based on injectable drugs, Denmark’s Novo Nordisk – the world’s biggest insulin maker – wants to prove during 2018 that it can transform the diabetes market with a pill.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

December 2018 Focus: Healthcare Agency Roundtable, Mobile Marketing, and more!


Ad Right Bottom